Owing to increasing resistance in Pseudomonas aeruginosa, empirical drug regimens may include agents to which some strains may be resistant. The purpose of this study was to evaluate the in vitro activities of different combinations of cephalosporin plus fluoroquinolone against P. aeruginosa isolates with varying susceptibility to the study drugs. Broth microdilution susceptibility testing was performed with 10 clinical isolates of P. aeruginosa. The bactericidal activity of cefepime or ceftazidime alone and in combination with ciprofloxacin, levofloxacin, gatifloxacin or moxifloxacin was evaluated using time-kill methods. Colony counts were determined at 0, 4, 8 and 24 h, using antimicrobial concentrations of 0.5 × MIC. All procedures were performed in duplicate. Synergy was defined as a >2-log decrease in cfu/mL at 24 h compared with the single most active agent. The MICs for tested strains were: ceftazidime 0.75-32, cefepime 0.125-8, ciprofloxacin 0.0078-8, levofloxacin 0.023-16, gatifloxacin 0.023-16 and moxifloxacin 0.0521-32 mg/L. Four strains were susceptible to all drugs, two strains were cephalosporin susceptible and fluoroquinolone resistant, and two strains were cephalosporin resistant and fluoroquinolone susceptible. Two strains were resistant or intermediately susceptible to all drugs. Various cephalosporin and fluoroquinolone combinations were synergic against P. aeruginosa, including strains resistant to one or both agents in combination. No synergy was observed in two strains susceptible to all drugs. There were no differences noted between different cephalosporin and fluoroquinolone combinations. Concentrations used in this study are clinically achievable with recommended regimens in most cases.
Introduction
Pseudomonas aeruginosa exhibits high-level resistance to many antimicrobials and, because of its ability to develop resistance during therapy, empirical treatment for serious systemic infections usually involves two-drug combination regimens. One such potentially favourable combination is a β-lactam plus a fluoroquinolone. Ciprofloxacin is usually perceived to have the greatest activity against P. aeruginosa on the basis of lower MICs. 1 However, other fluoroquinolones also possess in vitro activity against this pathogen and may have synergic activity with β-lactams, which would make them clinically useful for antipseudomonal therapy despite higher MIC values when tested as single agents.
We hypothesized that newer fluoroquinolones represent potentially effective agents for the treatment of P. aeruginosa infections when used in combination with potent antipseudomonal β-lactam agents. Thus, the purpose of this study was to compare the synergic effects of cefepime or ceftazidime in combination with ciprofloxacin, levofloxacin, gatifloxacin or moxifloxacin against clinical isolates of P. aeruginosa using time-kill methods. This technique was chosen because previous studies suggested that, compared with disc diffusion or chequerboard titration methods, time-kill assays correlate best with cure in animal models. 2, 3 
Materials and methods
MIC and time-kill assays were performed on 10 clinical isolates of P. aeruginosa obtained from the Clinical Microbiology Laboratory at the University of Colorado Hospital. Stock antibiotic solutions were prepared and dilutions made according to either the NCCLS M7-A5 method or manufacturer's recommendations. 4 The MICs were determined in duplicate by the microbroth dilution method in cation-supplemented Mueller-Hinton broth (Difco, Sparks, MD, USA) according to NCCLS methods. 4 Final antibiotic concentrations ranged from 0.0312 to 32.0 mg/L for cephalosporins and 0.0078 to 8.0 mg/L for fluoroquinolones. MIC microtitre plates were incubated aerobically at 35°C and read at 18-24 h. The final bacterial inoculum in each well was ∼7.5 × 10 5 cfu/mL. The MIC was defined as the lowest concentration at which there was no visible growth in microtitre wells. Susceptibility testing was again performed on isolates recovered from microtitre plates after completion of the time-concentration kill curve studies.
Bactericidal activity was determined using time-kill experiments according to the NCCLS M26-A method. 5 Antimicrobial concentrations tested were 0.5 × MIC as determined previously for each bacterial strain. The final inoculum was determined at time zero; viable counts were performed after 4, 8 and 24 h of incubation at 35°C. All tests were performed in duplicate. If discordant results were obtained, the experiment was repeated and quadruplicate data were used for analysis. The rate and extent of killing were determined by plotting viable colony counts (log 10 cfu/mL) against time. The lower limit of detection for time-kill assays was 1.3 log 10 cfu/mL.
Synergy and antagonism were defined as a ≥100-fold increase or ≤100-fold decrease, respectively, in bacterial killing and assessed at 8 and 24 h with the combination of drugs compared with the most active single agent of the combination alone. Additivity (or indifference) was defined as a <10-fold change increase (or decrease) in killing at 8 and 24 h with the combination in comparison with the most active single antimicrobial alone. To examine any differences between antibiotic combinations in a more quantitative manner, areas under the log 10 cfu/mL-time curves from time zero to 24 h (AUC 0-24 ) were calculated by the linear trapezoidal summation method. Lower calculated AUC 0-24 values represent more rapid and/or more complete bacterial killing over the 24 h assays compared with higher AUC 0-24 values.
Statistical analysis
One-way analysis of variance (ANOVA) was used with the Tukey test for post-hoc analysis to compare AUC 0-24 values between groups. A statistical P value of <0.05 was considered significant.
Results
Ceftazidime and cefepime had generally comparable in vitro activities against these 10 clinical isolates of P. aeruginosa, except that while ceftazidime-resistant isolates were included in the study, no cefepime-resistant isolates (MIC > 16 mg/L) were available from clinical specimens. Ciprofloxacin was the most active fluoroquinolone, and moxifloxacin the least active; levofloxacin and gatifloxacin were similar to each other in activity. Four isolates (numbers 53, 00-27, 47 and 49) were categorized as susceptible to all drugs (cephalosporin MICs 0.125-2.5 mg/L, fluoroquinolone MICs 0.0078-4 mg/L). Two isolates (numbers 00-14 and 8677) were cephalosporin susceptible (MICs 0.5-8 mg/L) and fluoroquinolone resistant (MICs 2-24 mg/L) and two isolates (numbers 9 and 10) were cephalosporin resistant (MICs 12-32 mg/L) and fluoroquinolone susceptible (0.125-2 mg/L). The final two isolates (numbers 8959 and 00-9) were non-susceptible (intermediate susceptibility or resistant) to all study drugs (cephalosporin MICs 16-32 mg/L, fluoroquinolone MICs 2-32 mg/L).
Activities of ceftazidime or cefepime in combination with each of the four fluoroquinolones are summarized in Table 1 . Synergic and bactericidal activities were evaluated at both 8 and 24 h to account for any drug inactivation occurring by 24 h. Representative time-kill curves of one isolate (P. aeruginosa number 00-14) are presented in Figure 1 . All ceftazidime plus fluoroquinolone combinations yielded synergic activity against 80% of strains. Similarly, the combination of cefepime plus ciprofloxacin resulted in synergic activity against 60% of strains tested, while synergic activity was noted against 70% of strains with combinations of cefepime plus levofloxacin, gatifloxacin or moxifloxacin. There were no significant differences in synergic activity between combinations of ceftazidime plus fluoroquinolone or cefepime plus fluoroquinolone when regimens were compared on the basis of calculated AUC 0-24 values (P = 0.83). Time-kill results were not substantially different for strains of P. aeruginosa categorized as susceptible to all drugs, cephalosporin susceptible/fluoroquinolone resistant, cephalosporin resistant/fluoroquinolone susceptible or non-susceptible to all drugs tested. Antagonism was not observed with any antimicrobial combination.
Susceptibility tests performed on isolates recovered after completion of time-kill studies revealed one-to four-fold increases in MIC after exposure to 0.5 × MIC of a single agent. Greater than two-fold increases in MIC during exposure to drug combinations were observed with combinations displaying additivity. However, with combinations displaying synergy, either no organism was isolated after 24 h time-kill assays, due to the bactericidal activity of the combination, or the MIC for recovered organisms was unchanged.
Discussion
The results of this study demonstrate that combinations of ceftazidime or cefepime plus a fluoroquinolone achieve in vitro synergy in ∼60-80% of tested P. aeruginosa clinical isolates. Rates of synergy in the present study are similar to, or higher than, those reported previously with these agents (∼25-75%). 2, [6] [7] [8] [9] Results of this study also indicate good synergic activity with antibiotic combinations including fluoroquinolones other than ciprofloxacin. Two previous studies also demonstrated synergy between levofloxacin and ceftazidime in 30-75% of test strains using time-kill methods; 2, 6 these results are similar to rates of synergy observed with combinations of ciprofloxacin plus ceftazidime. 7, 9 Gatifloxacin has also been shown previously to exert synergic effects in vitro when combined with β-lactam antibiotics. 8 Although synergy was not apparent when strains were susceptible to both agents in the combination, antibiotic combinations tested in the present study showed synergy in 34 of 37 cases (92%) when strains were resistant to one or both agents. In a previous report, ciprofloxacin plus ceftazidime was synergic in vitro by time-kill studies against nine of 12 strains (75%) resistant to one or both agents; ceftazidime MICs for resistant strains in this study were ∼32-64 mg/L and ciprofloxacin MICs were not given. 9 This study also noted that synergy was infrequent (<10%) when isolates were susceptible to both agents. In a second report, time-kill studies indicated synergy against all three strains resistant to ceftazidime (MIC 64-128 mg/L) but susceptible to levofloxacin (MICs 0.5-2 mg/L) when the drugs were tested in combination. 2 The potential for fluoroquinolones to act synergically with ceftazidime or cefepime against resistant isolates may prove advantageous when selecting empirical antibiotic therapy in institutions with high rates of drug resistance among P. aeruginosa.
The present study also demonstrated that combinations of ceftazidime or cefepime plus a fluoroquinolone effectively limited changes in antibiotic MICs and prevented the development of clinical resistance, even following exposure to drugs at sub-MIC levels. This may be attributable to the rapidly bactericidal activity that was observed with these drug combinations. These findings may have clinical relevance in that potentially synergic combinations of agents may help to slow or prevent the emergence of resistance among P. aeruginosa during antibiotic therapy, even among strains already possessing decreased susceptibility to one or both agents in the combination regimen. Ciprofloxacin, levofloxacin, gatifloxacin and moxifloxacin all demonstrated equivalent synergic effects against P. aeruginosa in vitro when tested at concentrations of 0.5 × MIC. However, clinically achievable plasma concentrations at customary dosages may be important limitations to use of certain fluoroquinolones intended to provide synergic effects. Mean peak plasma concentrations of ciprofloxacin 400 mg intravenously (iv) every 8 h and levofloxacin 500-750 mg iv every 24 h have been reported to be ∼5.0 and 8.0-12.0 mg/L, respectively. 10 Thus ciprofloxacin and levofloxacin should be capable of achieving plasma concentrations that are at least 0.5 × MIC for strains with MICs of ≤8 and ≤16 mg/L, respectively, one doubling dilution above the NCCLS susceptibility breakpoints. Both ciprofloxacin and levofloxacin would theoretically have been suitable for use against the clinical strains used in this experiment, with some expectation of synergy as part of combination antibiotic regimens, although the weight of previous clinical experience would perhaps favour ciprofloxacin for this use. Gatifloxacin and moxifloxacin both achieve mean peak plasma concentrations of ∼4.0-6.0 mg/L during dosing regimens of 400 mg iv every 24 h. 10 These drugs could be expected to achieve concentrations of 0.5 × MIC against strains for which the MICs is ≤8 mg/L (equal to the NCCLS breakpoint) but would not be expected to achieve adequate concentrations against more resistant strains. Thus gatifloxacin and moxifloxacin would have the greatest potential for synergy against intermediately susceptible strains of P. aeruginosa but would not be expected to achieve synergic effects against many more-resistant strains, as may perhaps be observed with ciprofloxacin and levofloxacin. In conclusion, ciprofloxacin, levofloxacin, gatifloxacin and moxifloxacin were all shown to have synergic activity against clinical isolates of P. aeruginosa when tested in combination with ceftazidime or cefepime. No significant differences were found in rates of synergy between ceftazidime or cefepime, or between the various fluoroquinolones. Synergy was observed particularly when bacterial strains were resistant to one or both agents in the combination tested. Although synergy was demonstrated in vitro for all fluoroquinolones, ciprofloxacin or levofloxacin would be the most suitable for routine empirical clinical use, based on clinically achievable drug concentrations with commonly used dosage regimens.
